ArticleJournal of medical virology2020
A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19.
Article in Journal of medical virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: A systematic review and meta-analysis.Immunity, inflammation and disease · 2021Pooled it
- Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version).Military Medical Research · 2020Guideline
- A systematic review and meta-analysis of the efficacy and safety of arbidol in the treatment of coronavirus disease 2019.Medicine · 2020Pooled it
- Enhanced Antiviral Activity of Novel Umifenovir Derivatives against SARS-CoV-2: Insights from an International Collaborative Study.ACS omega · 2026Article
- Arbidol: The current demand, strategies, and antiviral mechanisms.Immunity, inflammation and disease · 2023Review
- An overview on the treatments and prevention against COVID-19.Virology journal · 2023Review
- A systematic review and meta‑analysis of Arbidol therapy for acute respiratory viral infections: A potential treatment for COVID‑19.Experimental and therapeutic medicine · 2022Article
- Mapping the intersection of nanotechnology and SARS-CoV-2/COVID-19: A bibliometric analysis.Infectious medicine · 2022Article
- Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Corrigendum.Journal of medical virology · 2021Article
- Clinical Management of COVID-19: A Review of Pharmacological Treatment Options.Pharmaceuticals (Basel, Switzerland) · 2021Review
- A study on nursing effect of integrated traditional Chinese and Western medicine management mode on COVID-19.Japan journal of nursing science : JJNS · 2021Article
- Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19.Infection & chemotherapy · 2021Review
- COVID-19: Characteristics and Therapeutics.Cells · 2021Review
- FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2020Review
- A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19.Journal of medical virology · 2020Article
- Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.Virus research · 2020Review
- Current Options in the Treatment of COVID-19: A Review.Risk management and healthcare policy · 2020Review
- Directly Acting Antivirals for COVID-19: Where Do We Stand?Frontiers in microbiology · 2020Article
- A 21st Century Evil: Immunopathology and New Therapies of COVID-19.Frontiers in immunology · 2020Review
Corrections and comments
- Erratum issuedCorrigendum.2021
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
This study aims to explore the clinical effect of Arbidol (ARB) combined with adjuvant therapy on patients with coronavirus disease 2019 (COVID-19). The study included 62 patients with COVID-19 admitted to the First Hospital of Jiaxing from January to March 2020, and all patients were divided into the test group and the control group according to whether they received ARB during hospitalization. Various indexes in the two groups before and after treatment were observed and recorded, including fever, cough, hypodynamia, nasal obstruction, nasal discharge, diarrhea, C-reactive protein (CRP), procalcitonin (PCT), blood routine indexes, blood biochemical indexes, time to achieve negative virus nucleic acid, and so on. The fever and cough in the test group were relieved markedly faster than those in the control group (P < .05); there was no obvious difference between the two groups concerning the percentage of patients with abnormal CRP, PCT, blood routine indexes, aspartate aminotransferase, and alanine aminotransferase (P > .05); the time for two consecutive negative nucleic acid tests in the test group were shorter than that in the control group; the hospitalization period of the patients in the test group and control group were (16.5 ± 7.14) days and (18.55 ± 7.52) days, respectively. ARB combined with adjuvant therapy might be able to relieve the fever of COVID-19 sufferers faster and accelerate the cure time to some degree, hence it's recommended for further research clinically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.